

Index

Page numbers in *italics* refer to illustrations.

- abstract thinking, 27–28
- acetylcholine, 42–43
 - hormones and, 132
 - medications and, 249–250
 - supplements and, 219–222, 225–226, 228
 - vitamins and, 201
- acetyl-L-carnitine (ALC), 228–229
- A1C (glycosolated hemoglobin) test, 71
- Advil, 192–197
- aging, 2
- age-associated memory impairment, 32–34
 - brain changes and, 51
 - middle age and obesity, 89–91
 - of population, 4, 46–48
 - as risk factor, 62–63
 - underweight and, 90, 94–96
- AIDS dementia complex, 23
- ALCAR (acetyl-L-carnitine derivative), 228–229
- alcohol
 - alcohol-related dementia, 21–22
 - B₁₂ and, 201–202
 - benefits of, 157–159
 - Brain-Healthy Sangria, 162
 - dangers of, 156–157
 - J-curve and, 159, 159–161
 - pomegranate juice as alternative to, 161–162
 - quantifying, 158, 159–161
 - recommendations, 162–163
 - red wine, 160–161
 - wine in Mediterranean diet, 151–153
- aldehyde, 156–157
- alpha linoleic acid (ALA), 142–145, 215–216
- alpha-secretase, 38–39
- aluminum, 113
- Alzheimer, Alois, 10, 99
- Alzheimer's Association, 145–146, 155, 245
- Alzheimer's Disease
 - brain changes and aging, 51
 - as chronic disease, 256–264
 - cure vs. prevention, 48–51, 258
 - defined, 9–18
 - diagnosing, 16–17, 31, 101–103, 102, 245–247
 - myths about, 17–18, 113, 238
 - normal memory loss vs., 32–34
 - prevalence of, 19, 45–48, 50–52, 76
 - rate of decline from, 249

- Alzheimer's Disease (*continued*)
 research of, 52–56
 signs of, 24–28, 238–244, 248
 stages of, 12–16, 29–32, 48–49, 75, 76, 115–116, 248, 260
 types of dementia and, 18–24
See also brain; treatment;
individual risk factors
- Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), 195–197
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), 172
- Alzheimer's Disease Neuroimaging Initiative, 259
- Alzheimer's Questionnaire (AQ), 241–244
- Alzhemed (tramiprosate), 257
- American Academy of Neurology, 253
- American Diabetes Association, 81
- amyloid beta peptide, 11
- amyloid plaques, 10, 11, 36, 38, 38–39, 39
 alcohol and, 161
 blood pressure and, 125
 diabetes and, 84
 disease-modifying medications and, 257–259
 exercise and, 179–180
 hormones and, 66, 69
 obesity and, 93
See also beta-amyloid protein
- amyloid precursor protein (APP), 11, 38–39, 39, 93, 131–132
 cholesterol and, 171
 diet and, 151
 exercise and, 180
 gamma-secretase, 38–39, 39, 194–196
- amyotrophic lateral sclerosis (ALS), 21
- angioplasty, 104
- angiotensin-converting enzyme (ACE), 125
- antidepressants, 250–251
- anti-inflammatories, 191–197, 217–219, 257
See also inflammation
- antioxidants, 40, 146–149, 150–151, 206–211, 217–219, 226–227
- antipsychotic agents, 250–251
- apolipoprotein E (APO-E)
 alcohol and, 158–159
 anti-inflammatories and, 193
 antioxidants and, 149
 APO-Eε4, as biomarker, 260
 APO-Eε4, defined, 71–74
 APO-Eε4, discovery of, 263
 APO-Eε4 genotype, 71–77, 73
 cerebrovascular disease and, 104–105
 cholesterol and, 166, 170
 depression and, 116
 diet and, 141
 exercise and, 176
 genetics and, 64
- apoptosis, 161
- Aricept (donepezil), 249–250
- arrhythmic heart disease, 103
- arsenic, 111
- arteries, 99–103, 100, 102
 arteriosclerosis, defined, 99
 atherosclerosis, defined, 99
 atherosclerotic heart disease (ASHD), 103, 165
 blood pressure and, 122–123
 Circle of Willis atherosclerosis, 100, 100
 “hardening of,” 99, 102–103
- aspirin, 192
- Assess Your Risk of Getting Alzheimer's, 244
- Athena Diagnostics, 247
- Ativan (lorazepam), 251
- atorvastatin (Lipitor), 171–172, 172
- Avandia/Avandamet (rosiglitazone), 85
- Baltimore Longitudinal Study of Aging, 68, 116, 202–203
- bariatric surgery, 202

- Beach, Thomas, 100
 behavior, as symptom, 28, 250–251
 Bennett, David A., 184
 beta-amyloid protein, 38–39, 39, 93, 104–105
 alcohol and, 162
 anti-inflammatories and, 192, 194–195
 cholesterol and, 167, 171
 DHEA and, 224
 exercise and, 180
 See also amyloid plaques
 beta-blockers, 126–128
 beta-secretase, 38–39, 39
 biomarkers, 259–262
 blood tests
 for apolipoprotein E types, 71–77
 for cholesterol, 77–79
 for diabetes, 71
 for genetic influences, 63–65
 for homocysteine, 67–70
 for monitoring statin use, 168
 for thyroid function, 70
 blood thinners, ginkgo biloba and, 215
 blueberries, 149
 Body Mass Index (BMI), 88, 89, 90
 boxing, 117–119
 brain, 10, 35–44
 aging in, 51
 alcohol and, 157
 anti-inflammatories and, 192
 atrophy of, 35–37, 36, 37
 blood pressure and, 125
 chemical changes in, 42–43
 composition of, 141–142
 diabetes and, 82–86
 estrogen and, 66–67, 131–132
 fruits and vegetables for, 145–146
 lack of clinical symptoms and, 51–52
 neurofibrillary tangles, 10, 36, 40–42, 41, 104–105, 125, 179–180
 neurons, 35, 40, 41, 142
 obesity and, 91, 92
 PET scans of, 75–76, 245–246, 246
 PIB-PET scans of, 261, 261–262
 plaque, 37–39, 38 (*See also* amyloid plaques)
 synaptic damage to, 42
 See also cognition; *individual risk factors*
 Brain and Body Donation Program, 2, 63
 brain-derived neurotrophic factor (BDNF), 180
 Brain-Healthy Sangria, 162
 Breitner, John, 126
 Bronx Aging Study, 182–183
 B vitamins, 199–205
 Cache County (Utah) Study, 126, 132–133, 193, 209
 calcium channel blockers, 126–128
 CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) project, 93
 Canadian Study of Health and Aging, 119, 169, 176, 260
 carbon monoxide, 112
 cardiomyopathy, 103
 Cardiovascular Health Study, 90, 95, 102, 170, 206
 Caselli, Richard, 75
 Celebrex (celecoxib), 192, 194, 195–196, 197
 cerebrovascular disease, 98–106. *See also* stroke
 cerefolin (methylfolate), 204
 Chicago Health and Aging Project (CHAP), 142–145, 147, 148, 200, 209
 cholesterol, 164–174
 alcohol and, 161
 blood pressure and, 123
 diet and, 140–141
 HDL, 161, 166
 LDL, 161, 231
 Lipitor (atorvastatin) and cognition, 171–172, 172
 medications for, 164, 167–173

- cholesterol (*continued*)
 metabolic syndrome and, 96–97
 obesity and, 90, 92–93
 recommendations, 173–174
 testing for, 77–79
 triglycerides, 77–79
- choline, 225–226
- cholinesterase inhibitors, 249–250
- Chongqing Aging Study, 186–187
- Circle of Willis atherosclerosis, 100
- Cognex (tacrine), 249–250
- cognition
 boxing and head trauma, 117–119
 “cognitive killers,” 107
 cognitive reserve theory, 183–188
 decline in, 10, 17, 249
 depression and, 114–117
 recommendations, 120, 121
 sleep apnea and, 113–114
 smoking and, 119–120
 toxic exposure, 107–113
See also brain
- Columbia University, 184–185
- congestive heart failure, 103
- Connor, Donald, 107
- continuous positive airway pressure (CPAP) machines, 114
- copper, 111–112
- coronary artery bypass graft (CABG), 104
- cortisol, 223
- COX-2 inhibitors (cyclooxygenase-2 inhibitors), 194
- creatine phosphokinase (CPK), 168
- Creutzfeldt-Jakob disease (CJD), 23–24
- curcumin, 217–219
- C vitamins, 137–139, 206–211
- cyanocobalamin (B₁₂), 201–202
- cytokines, 38, 192
- dementia, 5
 distinguishing from Alzheimer’s, 246, 247
 “hardening of arteries” and, 99, 102–103
 with Lewy bodies (DLB), 19
 types of, 18–24
- dendrites, 132
- Depakote (divalproex sodium), 251
- depression, 22, 28, 114–117, 250–251
- DHEA (dehydroepiandrosterone), 222–224
- diabetes, 71, 81
 cognitive function and, 82–86
 defined, 82
 insulin and metabolic syndrome, 96–97
 obesity and, 92–93
 recommendations, 86
 tests for, 71
 type 1, 82
 type 2, 1, 71, 81, 82, 86–87
- Diabetes Control and Complications Trial (DCCT), 85–86
- diet, 54, 139
 antioxidants in, 146–149
 calorie restriction, 93
 green tea in, 150–151
 Mediterranean Diet, 151–153
 mercury in, 110
 omega-3 fatty acids in, 141–145
 recommendations for, 153–155
 sample menu, 154
 saturated fat in, 139–141
 vegetables and fruits in, 145–146, 149, 151–153
- dihydropyridine, 127
- disorientation, 27
- diuretics, 126–128
- divalproex sodium (Depakote), 251
- DMAE (dimethylaminoethanol), 226
- docohexaenoic acid (DHA), 142–145, 215–216
- donepezil (Aricept), 75, 249–250
- Down syndrome, 11
- Do You Have Alzheimer’s Disease? (questionnaire), 239–241
- educational level, 183–188
- icosapentaenic acid (EPA), 215–216

- Elan, 258
 emboli, spontaneous cerebral, 101
 embolic stroke, 98
 endocrine disorders, 23
 epigallocatechin-3-gallate (EGCG),
 150–151
 estrogen, 66–67, 130–136
 ethanol, 162
 E vitamin, 137–139, 206–211
 Exelon (rivastigmine), 249–250
 exercise. *See* mental exercise;
 physical exercise
- Farrer, Lindsay, 65, 170
 fibrillation, 40
 financial issues
 elder-care, legal documents,
 252–253
 patient care, 46–50, 75, 259
 research, 54, 264–265
- fish
 DMAE in, 226
 in Mediterranean diet, 151–153
 mercury in, 110
 omega-3 fatty acids in, 142–145
 omega-3 supplements, 215–216
 types of, 144
- flavonoids, 150–151, 214–215, 227
 Flurizan (tarenflurbil), 195, 257
 folic acid, 69, 199, 202–205
Forgetting, The (Shenk), 63
 Framingham study, 68, 92, 179
 free radicals, 40. *See also*
 antioxidants
- frontotemporal dementia (FTD), 20
 fruits, 145–146, 149, 151–153
 functional decline, 17
- galantamine (Razadyne), 249–250
 gamma-secretase, 38–39, 39,
 194–196
 genetics, 63–65
 APO-Eε4 genotype frequency, 73
 biomarkers, 259–262
 GETO (ginseng, epimedium herb,
 thinleaf milkwort root), 221
- Gingko Evaluation of Memory Study
 (GEMS), 214–215
 ginkgo biloba, 214–215
 Glenner, George, 11
 glia, 192
 glucose, 71, 81–87
 glycosaminoglycan (GAG), 257
 glycosylated hemoglobin (HbA1C)
 test, 71, 84
 grape seed extract, 226–227
 Green, Robert, 72–74, 170
 green tea, 150–151
 Guo, Zhenchao, 124
- Hadley, Evan, 93
 head injuries, 54, 117–119
 health care policy, 46–50
 heart disease, 50, 123
 heart attack, defined, 103
 stroke and Alzheimer's risk,
 103–105
 types of, 103
See also cholesterol; high blood
 pressure; stroke
- Hemoglobin A1C (glycosylated
 hemoglobin), 71, 84
 hemorrhagic stroke, 98, 117–119
 high blood pressure, 122
 angiotensin-converting enzyme
 (ACE) and, 125
 cognitive impairment and,
 123–124
 defined, 122–123
 metabolic syndrome and, 96–97
 obesity and, 90, 92–93
 recommendations for, 128–129
 treatment for, 126–128
- hippocampus, 91, 223
 HMG-CoA reductase inhibitors, 167,
 168
 homocysteine, 67–70, 203, 204–205
 Honolulu-Asia Aging Study, 91,
 94–95, 119, 127, 209
 HOPE study, 205, 210
 hormone replacement therapy
 (HRT), 130–136

- Huntington's disease, 21
 huperzine A, 219–221
 hypercholesterolemia, 167
 hyperhomocysteinemia, 67–68
 hyperlipidemia, 165
 hyperphosphorylation, 40
 hypertension. *See* high blood pressure
 hypothyroidism, 23, 69
- ibuprofen (Advil), 192–197
 Indocin (indomethacin), 192, 193
 inflammation, 23, 36, 171, 173, 191–197. *See also* anti-inflammatories
 insulin
 calorie restriction and, 93
 cognitive function and, 82–86
 insulin degrading enzyme (IDE), 84
 insulin-related-growth factor 1, 85
 metabolic syndrome and, 96–97
 See also diabetes
 ischemic damage, 125
- J-curve, alcohol and, 159, 159–161
 judgment problems, as warning sign, 27
 juices, 149
- Kaiser Permanente Group, 84, 91, 105
 Karolinska Institute (Sweden), 84, 105, 124
 Katzman, Robert, 10
 kidneys, 123, 125, 192–193, 196–197
 Korsakoff dementia, 22, 157
 Kramer, Arthur, 178–179
 Kungsholmen Project, 126
- lacunar stroke, 98
 language difficulty, 20, 26
 Launer, Lenore, 124
 lead, 109
- lecithin, 225–226
 legal issues, 252–253
 leukemias, 256
 Leuprolide (Lupron), 257–258
 Lewy, Frederic, 19
 Lewy bodies, dementia with (DLB), 19
 Li, Rena, 66–67
 life expectancy
 of Alzheimer's patients, 247–248
 of general population, 46
 lipids. *See* cholesterol
 Lipitor (atorvastatin), 171–172, 172
 liver function test (LFT), 168
 Loma Linda University, 162
 lorazepam (Ativan), 251
 loss of initiative, as warning sign, 28
 Lou Gehrig's disease (ALS), 21
- MacArthur Study of Successful Aging, 76
 mad cow disease, 23–24
 mamillary bodies, 157
 manganese, 111
 Mayo Clinic, 115, 133, 260–261
 Medical University of South Carolina, 140–141
 medication, 24, 43, 53
 antidepressants, 250–251
 anti-inflammatories, 191–197
 antipsychotics, 250–251
 approved for Alzheimer's, 248–249
 for blood pressure, 126–128
 blood thinners, 215
 for cholesterol, 168–169, 171–173, 172
 for diabetes, 71, 85
 efficacy of, 30
 future of, 257–259
 hormone replacement therapy, 130–136
 for memory, 75
 side effects from, 96
 See also supplements; vitamins

- Mediterranean Diet, 151–153
- memantine (Namenda, Ebixa), 249, 250
- memory, 3, 75
 - acetylcholine and, 42–43
 - DHA and, 142
 - estrogen and, 132
 - loss of, as warning sign, 25
 - tests, as predictors of Alzheimer's, 260
 - “training” for, 186
- men
 - blood pressure treatment in, 127–128
 - depression in, 116
 - estrogen and, 135–136
 - obesity and cognitive performance, 92
 - sleep apnea in, 114
- menopause, 130–136
- mental exercise, 182
 - educational level and Alzheimer's, 183–187
 - recommendations, 190
 - types of, 182–183, 187
- mercury, 109–110
- metabolic disorders, 23
- metabolic syndrome, 96–97
- methionine, 68
- methylation/demethylation cycle, 204–205
- methylfolate, 204
- microglia, 171, 173, 192
- microtubules, 40–41
- mild cognitive impairment (MCI), 12–13, 29–32, 48–49, 75, 76, 115–116
- Mini Mental State Examination (MMSE), 166, 206, 245, 249
- MIRAGE Study, 65, 116, 170, 173
- misplacing items, as warning sign, 28
- mitochondria, 228
- Monongahela Valley Independent Elders Survey (MoVIES), 158
- monounsaturated fatty acids, 152
- Motrin, 192–197
- Mount Sinai School of Medicine, 104
- Myriad Pharmaceuticals, 195, 257
- Namenda (memantine), 249, 250
- naproxen (Aleve), 194, 195–197
- National Cholesterol Educational Panel (NCEP), 78
- National Institute of Aging, 260
- neuritic senile plaques, 36, 37–40
- Neurochem, 357
- neurofibrillary tangles, 10, 36, 40–42, 41
 - blood pressure and, 125
 - exercise and, 179–180
 - heart disease and, 104–105
- Neuroimaging Initiative, 262
- neurons, 35, 40, 41, 142
- neuropsychological testing, 32, 246–247
- neurosteroids, 223
- neurosyphilis, 23
- neurotransmitters, 42–43, 131, 228
- niacin (B₃), 200–201
- nitrendipine, 127
- NMDA receptor antagonist, 250
- normal pressure hydrocephalus (NPH), 22
- NSAIDs (nonsteroidal anti-inflammatory drugs), 191–197, 257
- Nurses Health Study, 157–158
- obesity
 - Body Mass Index (BMI), 88, 89, 90
 - central obesity, 91–93
 - defined, 88
 - dementia risk from, 89–91
 - metabolic syndrome and, 96–97
 - “obesity paradox,” 90, 94–96
 - recommendations, 97
 - vascular risk factors from, 92–93
- occupation, as risk factor, 107–113
- olive oil, 151–153
- omega-3 fatty acids, 141–145
 - food sources, 143
 - supplements, 215–216

- OSHA (Occupational Safety and Health Administration), 112
- Ott, Ann, 119
- oxidative stress, 146–149, 167, 226
- paired helical filaments (PHF), 40
- Pamlab, 204
- pantothenic acid (B₅), 201
- paraphasia, 26–27
- Parkinson's disease, 19, 21
- Pauling, Linus, 206
- personality change, 28
- PET (positron emission tomography) scans, 75–76, 245–246
of normal vs. Alzheimer's brains, 246
PIB-PET, 261, 261–262
- pharmaceutical industry, 53
- phosphatidylserine (PS), 221–222
- phosphorylated tau, 40–41, 41, 104–105
- physical exercise, 54, 175–181
dancing, 183
easy exercises, 180–181
- phytoalexins, 230
- PIB-PET (Pittsburgh Compound B) scans, 261, 261–262
- Pick, Arnold, 20
- Pick's disease, 20
- plaque. *See* amyloid plaques; brain polyphenols, 149
- polysomnogram (PSG), 114
- polyunsaturated fatty acids, 152
- pomegranate juice, 149, 161–162
- potassium-sparing diuretics, 127–128
- Pratley, Richard, 93
- Premarin (conjugated estrogen tablets), 135
- presenillin test, 64
- Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVICE), 211
- progesterin, 133
- progressive supranuclear palsy, 21
- pyridoxine (B₆), 201
- Qian Ceng Ta, 219
- quercetin, 161, 226–227
- questionnaires
Alzheimer's Questionnaire (AQ), 241–244
Do You Have Alzheimer's Disease?, 239–241
- Razadyne (galantamine), 249–250
recommended daily allowances (RDA), 199
- red wine, 160–161. *See also* alcohol
- Reiman, Eric, 262
- Religious Orders Study, 76, 94, 95, 116, 184
- Relkin, Norman, 75
- Reminyl (galantamine), 249
- resveratrol, 160–162, 230–232
- REVEAL (Risk Evaluation and Education for Alzheimer's), 72–74
- R-flurbiprofens, 195, 257
- Ringman, John, 217
- rivastigmine (Exelon), 249–250
- Roher, Alex, 101
- rosiglitazone (Avandia), 85
- Rotterdam study (Holland), 126, 141, 147, 158, 193
- Sangria, Brain-Healthy, 162
- saturated fats, 139–141, 151, 231
- selegiline, 209–210
- Selenium and Vitamin E Cancer Prevention Trial (SELECT), 211
- Shenk, Dale, 63
- Shumaker, Sally, 133
- simvastatin (Zocor), 171–172, 173
- sleep apnea, 31, 113–114
- sleep disturbances, 251
- smoking, 119–120
- Snowdon, David, 184
- Sparks, Larry, 79, 103–104
- spinal fluid test, 247
- spontaneous cerebral emboli, 101

- statin drugs, 168, 171–172, 172, 173, 258
- stomach, 192–193
- stroke, 98
 - Alzheimer's link to, 98–103
 - B₁₂ and, 201
 - boxing and head injuries, 117–119
 - diabetes and, 83
 - high blood pressure and, 123
 - homocysteine and, 68
 - recommendations, 105–106
 - types of, 98–99
 - types of heart disease and, 103–105
 - vascular dementia and, 19–20, 99, 228–229
- structural lesions, 22
- Study on Cognition and Prognosis in the Elderly (SCOPE), 127
- subacute combined degeneration, 202
- Sun Health Research Institute, 2, 66, 171–172, 195–196
- supplements, 54
 - acetyl-L-carnitine, 228–229
 - antioxidants in, 147–149
 - choline and phosphatidylcholine, 225–226
 - curcumin, 217–219
 - DHEA, DHEA-S, 222–224
 - diet vs., 150
 - DMAE, 226
 - ginkgo biloba, 214–215
 - grapeseed extract and quercetin, 226–227
 - huperzine A, 219–221
 - omega-3 fatty acids, 215–216
 - phosphatidylserine, 221–222
 - recommendations, 232–233
 - resveratrol, 230–232
 - safety and effectiveness of, 212–213, 215, 222
 - vinpocetine, 229–230
 - See also* medication; vitamins
- synaptic damage, 36, 42, 218
- syphilis, 23
- Systolic Hypertension in Europe project (SYST-EUR), 127
- Systolic Hypertension in the Elderly Project (SHEP), 127
- tacrine (Cognex), 249–250
- task completion, as warning sign, 25–26
- tau, 40–41, 41, 104–105
- television watching, 187
- testosterone, 135–136
- thiamine (B₁), 200
- thiazolidinediones, 71, 85
- thrombotic stroke, 98
- thyroid, 23, 69, 70
- tocopherols, 208–211
- toxic exposure, 107–113
- tramiprosate (Alzhemed), 257
- transcranial Doppler, 101–103, 102
- treatment, 237–238
 - Alzheimer's Questionnaire, 241–244
 - approved medications for, 248–249
 - Assess Your Risk of Getting Alzheimer's, 244
 - awareness of symptoms and, 238–244
 - behavioral disturbances and, 250–251
 - diagnosis and, 245–247
 - Do You Have Alzheimer's Disease?, 239–241
 - future of medications in, 257–259
 - goals of, 247–248
 - hope for, 253
 - planning for patients' future and, 252–253
 - rate of decline and, 249
 - recommendations, 253–254
 - resource information, 245, 247, 251–252, 253
 - See also* diet; medication; supplements; vitamins

- tumors, 22
- turmeric, 217–219
- Tyas, Suzanne L., 119
- underweight, aging and, 90, 94–96.
See also obesity
- United Kingdom Medical Research Council, 119
- University of California
 Irvine, 32
 Los Angeles, 104, 218–219
 San Diego, 11
 San Francisco, 134, 224
- University of Colorado, 66
- University of Pittsburgh, 125, 261, 261–262
- University of Washington, 90, 126, 262
- vaccine-based therapies, 258
- valvular heart disease, 103
- vascular dementia, 19–20, 99, 228–229. *See also* stroke
- vasodilators, 229
- vegetables, 145–146, 151–153
- vinpocetine, 229–230
- vitamins
 B vitamins and folic acid, 199–205
 recommendations, 211
 recommended daily allowances (RDA), 199
 units of measure, 200
 vitamins C and E, 147–149, 206–211
 wellness industry, 198–199
See also medication; supplements
- Voyager Pharmaceuticals, 257–258
- Wernicke’s encephalopathy, 157, 200
- Whitmer, Rachel, 105
- whole-diet theory, 152–153
- Wilson’s disease, 111–112
- Wisniewski, Henry, 11
- women
 alcohol consumption by, 157–158
 Alzheimer’s frequency in, 65–67, 132
 cholesterol and, 166
 exercise and, 176–177
 hormone replacement therapy for, 130–136
 vegetable and fruit consumption by, 148–149
- Women’s Health Initiative, 130, 133
- Wong, C. W., 11
- Yaffe, Kristine, 96
- Zocor (simvastatin), 171–172, 173